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Abstract
We described an approach of identifying single nucleotide polymorphisms (SNPs) in complete genomic regions
of key genes including promoters, exons, introns, and downstream sequences by combining long-range poly-
merase chain reaction (PCR) or NimbleGen sequence capture with next-generation sequencing. Using the ade-
nomatous polyposis coli (APC) gene as an example, we identified 210 highly reliable SNPs by next-generation
sequencing analysis program MAQ and Samtools, of which 69 were novel ones, in the 123-kb APC genomic
region in 27 pair of colorectal cancers and normal adjacent tissues. We confirmed all of the eight randomly
selected high-quality SNPs by allele-specific PCR, suggesting that our false discovery rate is negligible. We
identified 11 SNPs in the exonic region, including one novel SNP that was not previously reported. Although 10
of them are synonymous, they were predicted to affect splicing by creating or removing exonic splicing en-
hancers or exonic splicing silencers. We also identified seven SNPs in the upstream region of the APC gene, three
of which were only identified in the cancer tissues. Six of these upstream SNPs were predicted to affect tran-
scription factor binding. We also observed that long-range PCR was better in capturing GC-rich regions than the
NimbleGen sequence capture technique.
Introduction
Colorectal cancer is one of the most common malig-nancies in Western countries as well as in China (Chiu
et al., 2003; Fodde, 2002). Mutations of the adenomatous poly-
posis coli (APC) gene, a gene first identified as the familial
adenomatous polyposis (FAP) locus gene (Kinzler et al., 1991),
contribute to colorectal tumorigenesis (Fodde, 2002; Miyoshi
et al., 1992; Sparks et al., 1998; Su et al., 1992). It is believed that
APC is a tumor suppressor, and that genomic and epigenetic
events causing the loss of the APC function are critical events
in colorectal tumorigenesis (Miyaki et al., 1997; Nagase and
Nakamura, 1993; Nakamura, 1993). The APC gene contains
multiple domains that can bind to various proteins, including
beta-catenin, axin, CtBP, Asefs, IQGAP1, EB1, and microtu-
bules (Aoki and Taketo, 2007). APC regulates the WNT=
beta-catenin signaling by forming a degradation complex
comprising of Axin, GSK-3b, and casein kinase (Smith et al.,
1993). Many different types of mutations can cause the loss of
these key function domains. Examples include mutations af-
fecting key amino acids in the binding domains, mutations
creating truncated proteins without the key domains, and
mutations that preclude the splicing of exons coding for these
key domains. Additionally, APC plays roles in several other
fundamental cellular processes including cell adhesion and
migration, organization of the actin and microtubule net-
works, spindle formation, and chromosome segregation.
Deregulation of these processes caused by mutations in APC
may also be implicated in colorectal cancer (Aoki and Taketo,
2007). Recently, Wood and coworkers (2007) have sequenced
1Systems Biology Division, Zhejiang–California International Nanosystems Institute (ZCNI), Zhejiang University, Hangzhou, People’s
Republic of China.
2Key Laboratory of Ministry of Education for Cell Biology and Tumor Cell Engineering, School of Life Sciences, Xiamen University, Fujian,
People’s Republic of China.
3Cancer Institute (Key Laboratory of Cancer Prevention and Intervention, China National Ministry of Education), The Second Affiliated
Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, People’s Republic of China.
4Swedish Medical Center, Seattle, Washington.
5Department of Urology, University of Washington, Seattle, Washington.
The first three authors contributed equally to this work.
OMICS A Journal of Integrative Biology
Volume 14, Number 3, 2010
ª Mary Ann Liebert, Inc.
DOI: 10.1089=omi.2010.0018
315
20,857 transcripts from 18,191 human genes of colorectal
cancer patients and identified the APC gene as the top-ranked
gene mutated in colorectal cancers. However, what were se-
quenced are mostly exonic sequences of the gene amplified by
conventional polymerase chain reaction (PCR).
With the advances in the next-generation sequencing
technologies, cancer genome sequencing and resequencing
have taken off. The sequencing and resequencing of the
cancer genome have taken two directions: some applica-
tions have focused on the identification for mutations in the
exons by genome wide amplification of exons followed by
sequencing. Recently finished genome-wide exon sequenc-
ing included breast and colorectal cancer (Wood et al.,
2007), pancreas cancer ( Jones et al., 2008) and glioblastoma
(Parsons et al., 2008). Another approach is to perform
complete genome sequencing for the cancer genome. The
first examples were done by Ley et al. (2008) and Mardis
et al. (2009), who sequenced a primary, cytogenetically
normal, de novo genome for acute myelogenous leukemia
(AML) with minimal maturation (AML-M1) and a matched
normal skin genomes using the Illumina’s sequencing
technology, and identified 12 acquired (somatic) mutations
within the coding sequences of genes and 52 somatic point
mutations in conserved or regulatory portions of the genome.
Later, Shah et al. (2009) used the Illumina sequencing-based
approach to sequence the genome of a primary tumor, as
well as a metastasis collected from the same patient 9 years
later, and they found that, of the 32 somatic alterations
detected in metastasis, only 11 were detected in primary
tumor. Recently, Clark et al. (2010) sequenced a grade IV
glioma cell line U87MG and found that 512 genes were
homozygously mutated, including 154 by single nucleotide
variants (SNVs), 178 by small indels.
In contrast to the above approach, we tested an approach of
targeted amplification or capture of complete genomic re-
gions of genes including upstream, exonic, and intronic, as
well as downstream sequences, followed by next-generation
sequencing, for efficient identification of single nucleotide
polymorphisms (SNPs) in a large number of samples. We
used the APC gene, which is the most well-studied and
thoroughly sequenced gene for its critical role in colorectal
cancer formations (Fodde, 2002; Nagase and Nakamura, 1993;
Nishisho et al., 1991; Smith et al., 1993; Wood et al., 2007), as
an example. In the initial targeted sequencing for SNP
screening, we pooled 27 colorectal cancer samples and 27
normal adjacent tissues. We identified a total of 210 SNPs in
the colorectal cancers and normal adjacent tissues, of which 69
were novel ones. Eleven SNPs were identified in the exons of
the APC gene and one of them is a novel SNP that had not
been previously reported in the Ensembl SNP database. Eight
of these SNPs are in the coding regions and seven of the them
are synonymous SNPs. Interestingly, although these SNPs do
not change the amino acids, they were predicted to affect
splicing by either gain or loss of an exonic splicing enhancer or
an exonic splicing silencer. Confirmational studies by allele-
specific PCR approach of eight randomly selected SNPs sug-
gested that the 210 SNPs that we identified have a negligible
false discovery rate. As a byproduct of this study, we also
compared the resequencing results from long-range PCR to
that from NimbleGen sequence capture technology, and
found that most variations indentified were common between
these two methods. However, we observed that long-range
PCR was better in capturing GC-rich regions than the Nim-
bleGen sequence capture technique.
Materials and Methods
Clinical samples and genomic DNA isolation
Tissue samples were obtained from 6 control subjects
(healthy individuals) and 37 colon cancer patients. All sub-
jects are of Chinese origin. Samples were collected with an
institutional review borad approval. DNAs were isolated
using the DNeasy Blood & Tissue Kit (Qiagen Inc., Valencia,
CA, USA) according to the manufacturer’s protocol.
Long-range PCR
To amplify the genomic region of the APC gene, 14 pairs of
specific primers were designed using the Primer 3 program
(Rozen and Skaletsky, 2000) from the Human APC gene
(Ensembl Gene ID ENSG00000134982) including 10 k up-
stream and 5 k downstream region. Primer sequences and
their annealing temperature are shown in Supplementary
Table 1. Amplifications of DNA were performed by PCR in a
25 mL volume containing 1 Long-range PCR Buffer with
2.5 mM Mg2þ, 500mM of each Dntp, 0.4 mM of each primer and
1 unit of Long-range PCR Enzyme Mix (Qiagen Inc.). The PCR
reaction was performed the following thermal cycling profile:
an initial denaturation at 938C for 3 min, 10 cycles of reactions
with each cycle at [938C for 15 s, the annealing temperature
(the annealing temperature is listed in Supplementary Table 1
and varies for each primer pairs) for 30 s, and 688C for 11 min],
followed by another 28 cycles of reactions with each cycle at
(938C for 15 s, the annealing temperature for 30 s, and 688C for
11 min with an extension of 20 s at each additional cycle), and
a final extension at 688C for 10 min. After amplification, PCR
products were purified using the QIAquick PCR Purification
Kit and the QIAquick Gel Extraction Kit (Qiagen Inc.) when
the PCR products were run by electrophoresis and specific
bands were cut out.
NimbleGen sequence captures
A custom tiling 385-k sequence capture array targeting the
APC genomic sequence (Chr 5, coordinates 112091483–
112214834 bp) was designed and manufactured by Roche
NimbleGen. The 1:1 ratio of mixed genomic DNAs from 30
colon cancer patients were shipped to Roche NimbleGen
(Madison, WI, USA). Briefly, the genomic DNA sample was
fragmented, and then hybridized to the custom NimbleGen
Sequence Capture array. Unbound fragments were removed,
and the target-enriched DNAs was eluted and amplified as
described (Albert et al., 2007; D’Ascenzo et al., 2009; Droege
and Hill, 2008; Okou et al., 2007).
Sequence analyses by the next generation
sequencing technologies
Amplified DNAs were sonicated for 10 min (130w, Cole-
Parmer CPX 130, Vernon Hills, IL, USA) to generate DNA
fragments of an average size of 500 bp. The DNAs were fur-
ther purified and concentrated with Qiaquick PCR purifica-
tion spin columns (Qiagen Inc.). Genomic fragments were
end-repaired by a mixture of T4 DNA polymerase, Klenow
DNA polymerase, and T4 PNK (Promega, Madison, WI, USA)
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and a 30 overhang A was added using the Klenow exo-
enzyme (Promega). The resultant fragments were ligated with
the Illumina’s classical adapters by DNA T4 ligase (Promega)
according to the Illumina’s protocol. Adapter-linked DNA
fragments were separated by agarose gel electrophoresis and
the band between 150–200 bp was excised from the gel. The
DNA fragments were extracted from the agarose slices using
the Qiaquick Gel Extraction Kit (Qiagen Inc.). Extracted
DNAs were enriched by an 18-cycle amplification using Illu-
mina’s universal adapters. The DNA fragments were purified,
quantified, and then sequenced for 36 cycles using the Illu-
mina’s protocol.
Short sequence read mapping and SNP calling
Short-sequence reads were extracted from the image files
with the Illumina’s Firecrest and Bustard programs and
mapped to the Human APC reference genome sequence
(ENSG00000134982, including 10 k upstream and 5 k down-
stream region) by BWA (version 0.5.3) with default parame-
ters. BWA is an efficient program for aligning relatively short
nucleotide sequences against a long reference sequence al-
lowing mismatches and gaps, thus to find both SNPs and
indels (Li and Durbin, 2009).
SNPs and indels were identified by samtools (version
0.1.6), which migrated and improved various downstream
data processing implemented in Maq=Maqview, such as in-
dexing, pileup, viewer, and consensus caller. Samtools gen-
erated the consensus sequence with the statistical model
implemented in MAQ (Li et al., 2008, 2009). Potential PCR
duplicates were first removed by command ‘‘samtools
rmdupse.’’ Raw variations were called by command ‘‘sam-
tools pileup’’ with default parameters, and then filtered by
command ‘‘samtools.pl varFilter’’ with default options except
following: minimum read depth (d 5) to filter out low cov-
ered region, maximum read depth (D 255) to filter out ran-
domly placed repetitive hits. Those SNPs with SNP quality
scores greater than 45 were considered as high-quality ones.
Detecting regions of no or low read coverage
Regions of no or low read coverage might be caused by
either ineffective sequence capture or inaccuracy short reads
mapping. GC content might affect Solexa base calling and
PCR amplification, and low complexity regions might affect
short reads mapping. GC content and read coverage were
computed in a 100-bp window, and correlation coefficients
(Spearman method) were computed using R (www.r-project
.org). We computed the average coverage for both before
and after removing PCR duplicates in a 100-bp window. Re-
peat and low complexity regions were found by cross_match
program (Phrap package) with default parameters. Those
low-complexity regions that were similar to others found in
the human genome can cause ambiguity for mapping.
Prediction of functional consequences of SNPs
The final filtered SNPs were first compared to Ensembl
variation database (version 55) to find novel ones using cus-
tom perl scripts. The online tool SNPnexus was then used for
functional annotation for the SNPs. SNPnexus is a database
providing a complete set of functional annotations of SNPs,
including consequences to genes and regulatory elements
(Chelala et al., 2009). The functional consequences of these
SNPs on splicing were predicted by programs ESEfinder
(Cartegni et al., 2003), or RESCUE-ESE (Fairbrother et al.,
2002) for ESE prediction, and by the FAS-ESS program (Wang
et al., 2004) for ESS prediction. The outcomes of the prediction
was integrated using the online tool FASTSNP (Yuan et al.,
2006), which was written as a central server to connect to
various SNP function prediction programs.
We used PROMO, a program to detecting known tran-
scription regulatory elements using species-tailored searches
(Farre et al., 2003; Messeguer et al., 2002), to predict whether a
SNP affects transcription factor (TF) binding. DNA sequences
10 nucleotides on either side of the SNP were used as inputs,
and the TF species for human was selected and TF sites of all
species were selected.
Confirmation of the APC SNPs
To confirm SNPs identified by the next-generation se-
quencing techniques, we performed allele-specific PCR (AS-
PCR) (Wangkumhang et al., 2007; Ye et al., 2001) in a cohort of
24 pairs (48 samples) of individual colorectal cancer samples
and 6 health volunteers. We employed the Tetra-primer am-
plification refractory mutation system (ARMS)-PCR, which is
an efficient procedure for genotyping single nucleotide
polymorphisms developed by Ye et al. (Wangkumhang et al.,
2007; Ye et al., 2001). In brief, primers were designed using the
online program for designing Tetra-primer ARMS-PCR
primers (http:==cedar.genetics.soton.ac.uk=public_html=primer1
.html) (Ye et al., 2001). Each PCR reaction was carried out in a
total volume of 10mL, which contains 1 TAKARA Ex Taq
Buffer, 2.5 mM Mg2þ, 250mM of each dNTP, 0.2mM of each
primer, and 5 U=mL. TaKaRa Ex Taq. The results were then an-
alyzed by 2% agarose gel electrophoresis.
Results
Identification of 210 highly confident SNPs
in the APC gene
Using long-range PCR, we successfully amplified the
complete APC genomic region (123 kb) including the 10-kb
upstream and 5-kb downstream sequences using 14 10 kb-size
PCR reactions from 27 pairs of colorectal cancer and adjacent
tissue samples. The PCR primers used for the long-range PCR
are shown in Supplementary Table 1. The coverage of the
long-range PCR is 100% as we successfully amplified each
region of the APC gene. The same amount of DNAs from 14
PCR products each from 27 colorectal samples (total of 378
PCR products) were pooled and subject to next-generation
sequencing. The same procedure was carried out for the 27
adjacent colorectal samples. Amplification of individual
sample before pooling, instead of pooling the samples and
then performing PCR, ensured that the 27 pairs of individuals
were equally represented in the final product for sequencing.
This is important, as we found that different genomic prepa-
rations often have different efficiencies for PCR (data not
shown), and therefore, mixing the samples before PCR may
introduce bias in the final representation of samples.
In addition, we also used the NimbleGen sequence capture
technology (Roche Diagnostics, Asia Pacific) to capture the
same genomic region, as a test to see if it can replace the labor
intensive long-range PCR. As the cost of doing NimbleGen’s
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capture for each sample in very costly, we decided to pool the
samples into the cancer sample pool and the normal adjacent
sample pool, and then sent to NimbleGen for performing se-
quence capture. Regions in the APC gene that have repeats or
low-complexity sequences were not targeted for capture in the
NimbleGen sequence capture technology as no probes were
designed in this region.
Short-sequence reads were first from aligned to the Hu-
man APC reference genome sequence (ENSG00000134982)
including the 10-k upstream and 5-k downstream region by
BWA (version 0.5.3) (Li and Durbin, 2009) with default pa-
rameters. BWA is an efficient program for aligning relatively
short nucleotide sequences against a long reference sequence
allowing mismatches and gaps, thus to find both SNPs and
indels (Li and Durbin, 2009). Repeat sequences that matched
to more than one locations were filtered out. SNPs and indels
were identified by samtools (version 0.1.6) and MAQ (Li
et al., 2008, 2009). After the analysis, the SNPs with SNP
quality score greater than 45 were considered as high-quality
ones.
In the end, we identified 210 SNPs in the APC gene, of
which 69 were novel SNPs (Table 1 and Supplementary
Table 2) that were not found in the SNP database. We also
created a bedGraph format file for all the SNPs identified for
easy upload to the UCSC genome browser for viewing the
SNPs along with the genome annotations (Supplementary
Table 3). Most of the SNPs were identified in the introns.
Seven SNPs were identified in the upstream region. Eleven
SNPs were located in exons (Table 2). Ten of them are syn-
onymous SNPs and one is a nonsynonymous SNP. We also
identified one novel SNP (at human genome HG19 position
Chr5:112179745) that was not reported previously (Table 2).
In addition, we observed that the SNP is not evenly dis-
tributed across the APC gene (Fig. 1). However, the func-
tional consequences of this observation remain to be studied.
Predicted functional consequences
of the SNPs identified
As our approach not only identified SNPs in the coding
exons, but also identified SNPs in the upstream sequences,
introns, and down stream sequences, a more comprehensive
analysis of the function of the SNPs identified, rather than
simply annotating them with synonymous or nonsynony-
mous coding SNP, is needed. Human genes are regulated by
diverse cis-acting elements to make the correctly spliced
mRNAs at the right place and at the right time. SNPs affecting
these regulatory elements of splicing will affect gene splicing,
which was shown to contribute greatly to many human dis-
ease including cancers (Cartegni et al., 2002; Wang and
Cooper, 2007). These regulatory elements include the intronic
and exonic splicing enhancer (ISE and ESE) (Cartegni et al.,
2003) and suppressor (ESS and ISS) elements (Wang et al.,
2004). ESEs are cis-regulatory elements that direct or facilitate
accurate splicing of precursor RNAs (Cartegni et al., 2003) and
ESSs are cis-regulatory elements that inhibit the use of adja-





















112162854 112190753 99271 T C=T 486 rs2229992 SYNONYMOUS_CODING ESE gain;
ESS loss
112164561 112192460 100978 G A=G 545 rs351771 SYNONYMOUS_CODING ESE gain
112175770 112203669 112187 G A=G 1493 rs41115 SYNONYMOUS_CODING ESE gain
112176325 112204224 112742 G A=G 1678 rs42427 SYNONYMOUS_CODING ESE gain;
ESS loss
112176559 112204458 112976 T G=T 1756 rs866006 SYNONYMOUS_CODING ESE loss
112176756 112204655 113173 T A=T 1822 rs459552 NONSYNONYMOUS:V-D ESE gain
112177171 112205070 113588 G A=G 1960 rs465899 SYNONYMOUS_CODING N=A
112179745 112207644 116162 C A=C 2818 Novel SYNONYMOUS_CODING ESE loss
112180921 112208820 117338 T C=T rs41116 30UTR N=A
112181379 112209278 117796 C G=C rs448475 30UTR ESE gain
112181576 112209475 117993 G A=G rs397768 30UTR ESE gain;
ESS loss
SNP, single nucleotide polymorphism; ESE, exonic splicing enhancer; ESS, exonic splicing suppressor.
Table 1. Summary of the overall SNPs of the APC Gene in All the Four Sequencing Results
In all PCR_C PCR_N NG_C NG_N
SNPs 210 154 137 135 151
Novel SNPs 69 23 14 18 30
Exonic variations 11 11 10 10 10
Missense variations 1 1 1 1 1
Variations that may change splicing 9 9 8 8 8
Variation may affect transcription binding 7 6 2 4 3
SNPs, single nucleotide polymorphisms.
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cent splice sites (Wang et al., 2004). ESEs can bind SR proteins
and recruit and stabilize proteins necessary to splicing in the
spliceosome while ESSs can bind protein components of het-
erogeneous nuclear ribonucleoproteins (hnRNP) to repress
exon usage (Wang and Cooper, 2007).
Using the online tool FASTSNP (Yuan et al., 2006) to predict
ESE or ESS gain or loss, we found that seven of the eight
synonymous SNPs in the coding region affected splicing by
either an ESE or an ESS gain or loss (Table 2). Two of the three
SNPs in the 30 UTR region also resulted in an ESE=ESS gain or
FIG. 1. Read depth and distribution of each SNP of the APC gene in CRC. The height of each histogram represented read
depth of corresponding SNPs, and the X-axis represents the position in APC reference (including 10 k upstream in the first
and 5 k downstream in the end). The red regions were the CDS of the APC gene, and the green were UTR. The conserved
transcription factor binding sites and miRNA target sites were labeled as black and blue.
Table 3. SNPs in the Upstream Sequence of the APC Gene and Their Effects on TF Bindings
Position in HG19
chromosome (bp) Reference bases Read bases Affected TF binding
112063970 G G=C Gain of binding of WT1 I–KTS
[T00900], WT1–KTS [T01839] and
ETF [T00270]
112064475 A A=T Loss of PR B [T00696] and
PR A [T01661] binding, a gain of
c-Myb [T00137] binding
112064826 G C Loss of CUTL1 [T00100] and SRY
[T00997]
112066524 G C gain of p300 [T01427], R2 [T00712],
NFI=CTF [T00094] and
Elk-1 [T00250]
112067142 C C=T gain of YY1 [T00915] and gain of
additional site (from one to two) of
ENKTF-1 [T00255]
112070456 G A=G Loss of c-Ets-1 [T00112], R2 [T00712]
binding
112070490 G G=T No effect
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loss (Table 2). The one nonsynonymous SNP also resulted an
ESE gain (Table 2). It should be pointed out that this non-
synonymous SNP was predicted by PolyPhen, which predicts
possible impact of an amino acid substitution on the struc-
ture and function of a human protein (http:==genetics.bwh
.harvard.edu=pph=) (Ramensky et al., 2002), to only have
benign effect on protein function (the PSIC score difference
was 0.532). However, it resulted in a gain of an exonic splicing
enhancer.
We also identified seven SNPs in the upstream sequence
(putative promoter regions) of the APC gene (Supplementary
Table 2). We used PROMO, a program for detecting known
transcription regulatory elements using species-tailored
searches (Farre et al., 2003; Messeguer et al., 2002), to predict
whether these SNPs affect transcription factor binding. We
found that SNP at position chr 5: 112070456 (G->A) (all po-
sitions refer to the human genome HG19 position) would
predict to have losses of two transcription factor bindings—c-
Ets-1 [T00112] and R2 [T00712] (Table 3). The SNP at position
chr 5: 112067142 (C->T) would result in a gain of YY1 binding,
and a gain of additional binding sites to ENKTF-1 (from one
site to two sites). The SNP at position chr 5: 112066524 (G->C)
would result in gains of four TF binding sites for p300
[T01427], R2 [T00712], NFI=CTF [T00094], and Elk-1 [T00250].
The SNP at position chr 5: 112064826 (G->C) would result in
the loss of binding to CUTL1 [T00100] and SRY [T00997]. The
SNP at position chr 5: 112064475 (A->T) would result in the
loss of PR B [T00696] and PR A [T01661] binding, but a gain of
c-Myb [T00137] binding. The SNP at position chr 5: 112063970
(G->C) would result in gains of binding to WT1 I -KTS
[T00900], WT1 -KTS [T01839], and ETF [T00270] (Table 3).
Our approaches identified a large number of SNPs in the
introns of the APC gene. Recent genomic data showed that
introns contain functional important regions such as the
conserved intronic splicing regulatory elements (ISREs) that
are important for gene regulation and splicing (Yeo et al.,
2007). These ISREs include ISEs and ISSs. ISEs can enhance
exon definition and activate weak exons, whereas ISSs can
inhibit exon definition by recruiting splicing repressors and
created a zone of silencing (Chou et al., 2000; Singh et al., 1995;
Valcarcel et al., 1993). We found that many of the SNPs that
we identified were located on the evolutionary conserved
intronic regions using the UCSC genome browser view (data
not shown). However, as there is no reliable prediction pro-
gram for detecting the effect of SNPs in the ISRE regions, the
functional consequences of these SNPs remain to be deter-
mined.
Confirmation of SNPs by allele-specific PCR (AS-PCR)
To confirm the SNPs that we identified by our approach are
genuine SNPs, we performed AS-PCR for randomly selected
SNPs. We used the tetra-primer allele specific PCR method,
which is a simple and economical method for SNP genotyping
and confirmation (Ye et al., 1992, 2001). To increase discrim-
inating power of AS-PCR, we introduced an additional mis-
match at position 2 from the 30-terminus, an approach that
was shown to increase the specificity of classical allele-specific
PCR (Ye et al., 1992, 2001).
We randomly chose 10 SNPs with various SNP quality
scores for confirmation by AS-PCR (Table 4): 8 SNPs had
SNP quality scores >45, and 2 had SNP quality scores <45.
We performed AS-PCR on DNAs from 24 pair of cancer and
adjacent benign tissues (a total of 48 cancer samples) and
6 healthy individual controls. All of the eight SNPs with high
SNP quality were successively confirmed including the one
novel SNP, which was confirmed in both in the cancer and
the normal adjacent tissues (Table 4). However, for the two
SNPs with quality score less than 45; one was confirmed and
another one was not (Table 4). Figure 2 shows the AS-PCR
result for the confirmation of the SNP at position chr5:
112074356 (C>T). The result showed that the T allele at this
position is the common allele in the Chinese populations. As
we used the score of45 as the cutoff score for our identified
SNPs, and the eight SNPs with scores 45 were all con-
firmed, the false positive rate of the 210 SNPs that we iden-
tified is therefore negligible. The stringent score we used for
selecting SNPs ensured the quality of the SNPs identified.
However, we might miss some potential SNPs using such a
stringent score.







APC ref Ref_base Read_base SNP quality Confirmed
rs2020383 112102255 112074356 10773 C C=T >45 Yes
Novel 112154244 112126345 62762 T C=T >45 Yes
rs351771 112192460 112164561 100978 G A=G >45 Yes
rs41115 112203669 112175770 112187 G A=G >45 Yes
rs42427 112204224 112176325 112742 G A=G >45 Yes
rs459552 112204655 112176756 113173 T A=T >45 Yes
rs465899 112205070 112177171 113588 G A=G >45 Yes
rs397768 112209475 112181576 117993 G A=G >45 Yes
Novel 112129976 112102077 38494 G G=T <45 Yes
Novel 112207859 112179960 116377 G A=G <45 No
SNP, single nucleotide polymorphism.
FIG. 2. Validation of SNP at position chr5: 112074356
(C>T) by AS-PCR. The PCR products for the T allele ap-
peared in 16 samples, wherease the C allele only appeared in
8 samples, suggesting that 8 samples were heterozygous C=T
and 8 samples were homozygous for the T allele.
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Comparing target selection by long-range PCR
and sequencing capture technology
for next-generation sequencing
We investigated the distributions of SNPs identified in
cancer and normal adjacent tissues using the two methods.
We found that about half of the SNPs (52%, 109 of 210 SNPs)
were identified to be common among the four comparisons:
PCR-C (DNAs amplified by PCR from cancer samples), PCR-
N (DNAs amplified by PCR from normal adjacent samples),
NG-C (DNAs captured by the Nimblegen’s technology from
cancer samples), and NG-N (DNAs captured by the Nimble-
gen’s technology from normal adjacent samples) (Fig. 3).
Comparing the SNPs between cancer and normal adjacent
samples, we identified a total of 37 SNPs (22 from PCR-C, and
11 from NG-C) that were only identified in the cancer samples
(Supplementary Table 2). Four of these SNPs have predicted
functional consequences. The one coding SNP at position
112179745 (C to A) would result in an ESE loss. The other
three SNPs were located in upstream sequences of the APC
gene and would have predicted gain or loss of TF bindings
(Table 5). For example, SNP 112070456 (G to A) would result
in the loss of c-Ets-1 [T00112] and R2 [T00712] binding.
However, most of the cancer specific SNPs that we identified
are in the introns; whether and how these SNPs are related to
colorectal cancer remains to be investigated.
We plot the sequence coverage across the APC gene using
only the uniquely mapped sequence tags, and we found that
the coverage is on average about the same (Fig. 4). However,
we did notice that for the GC rich region, the PCR approach
seemed to perform better than the NimbleGen’s target cap-
ture approach. For the GC region marked by an arrow in
Figure 4, the PCR approach (the PCR-C panel) has much
higher coverage than the NimbleGen’s capture approach (the
NG-C panel). Please note the most of the low coverage re-
gions in our analysis was due to filtering out the tags that are
either repeats or are low complex sequences (marked by blue
boxes in Fig. 4).
Discussion
In this report, we tested a targeted genomic amplification
and capture approach for sequencing a predetermined ge-
nomic region in a large number of samples using the next-
generation sequencing technology for SNP discoveries. Our
approach and analysis pipeline is summarized as follows: we
first amplified by long-range genomic PCR or captured by
NimbleGen’s sequence capture technology a predetermined
region followed by next-generation sequencing to identify
SNPs using pooled samples. Data were then analyzed by
BWA (Li and Durbinm, 2009) followed by samtools (Li et al.,
2009). SNPs identified were confirmed using AS-PCR
(Wangkumhang et al., 2007; Ye et al., 2001) in a large cohort of
individual samples. Finally, annotations and functional con-
sequences of SNPs were performed using bioinformatics tools
SNPnexus and FastSNP (Chelala et al., 2009) (Yuan et al.,
2006).
FIG. 3. Comparison of SNPs identified from CRC cancer
and cancer adjacent tissues using either long-range PCR or
the NimbleGen sequence capture technology. PCR-C: SNPs
identified in the PCR amplified CRC samples; PCR-N: SNPs
identified in the PCR amplified normal adjacent samples;
NG-C, SNPs identified in the NimbleGen captured CRC
samples; NG-N: SNPs identified in the NimbleGen Captured
normal adjacent samples.





base Read bases Region Functional consequences





112067142 C C=T upstream gain of YY1 [T00915]
and gain of additional
site (from one to two)
of ENKTF-1 [T00255]
112179745 C A=C coding ESE loss
112070456 G A=G upstream Loss of c-Ets-1
[T00112], R2
[T00712] binding
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Using the APC gene as an example, we sequenced the
whole genomic region of the APC gene (123 kb) in 27 pair of
cancer and normal adjacent tissues of Chinese sporadic colo-
rectal cancer patients, including its 10-kb upstream and 5-kb
downstream regions. We identified 210 SNPs in total (Sup-
plementary Table 2 and Table 1), of which 69 are novel SNPs
that have not been reported in the Ensembl Database (release
55), which contains a total of 628 SNPs identified for the APC
gene. Our analysis suggests that targeted capture or amplifi-
cation of a predetermined genomic regions followed by the
next-generation sequencing is an effective way of identify
SNPs in a large number of patients without going for com-
plete sequencing of the whole genome. This approach will be
effective in quickly assessing the spectrum of the SNPs in
important genes or genomic regions affecting cancers such as
the APC gene that we used as an example for the colorectal
cancer. Our approach not only identifies SNPs in exons, but
also SNPs in introns and up- and downstream regions, which
have been recognized more and more as playing important
roles in gene regulation and human diseases ( Jaillon et al.,
2008). Our approach was tested when the bar-coding tech-
nology for next-generation technology was still immature.
Recent advances in labeling multiple samples with bar-coding
adapters prior to the next-generation sequencing (Cronn et al.,
2008) may offer a more effective approach by eliminating the
sample pooling step.
The adenomatous polyposis coli (APC) gene is mutated in fa-
milial adenomatous polyposis (FAP) patients and in most
sporadic colorectal tumors. In the mutation database mutDB
(http:==mutdb.org=cgi-bin=mutdb.pl?id¼APC&geneid¼324),
there are 47 nsSNPs (nonsynonymous SNPs) and 11 synon-
ymous SNPs for the APC gene identified to be associated with
FAP, colorectal cancer, or gastric cancer. In particular, muta-
tions V890I, S906Y, E911G, Y1027C, T1313A, and A1508V
were identified in colorectal carcinoma (Miyaki et al., 1997)
(http:==mutdb.org=cgi-bin=mutdb.pl?id¼APC&geneid¼324).
In this study, we have identified one novel SNP (Table 2),
expanding the number of mutations that are associated with
colorectal cancers. Some of the 69 novel SNPs (Supplementary
Table 2) that we identified might be unique to the Chinese
population, similar to the observation that the mutation pat-
terns of the APC gene in FAP patients in different populations
are different (Attard et al., 2007). Comparison between Cau-
casian and Chinese using a large cohort of individuals is
needed to answer this question.
The APC gene (ENSG00000134982) contains 16 exons and
encodes a protein of 2,843 amino acid residues. The APC
protein contains several domains: an oligomerization domain
FIG. 4. Plots of sequence coverage of the APC gene by the next-generation sequencing. The red lines show the sequence
read depth of the corresponding bases, and the green lines show the GC content of a 100-bp window. The blue blocks were
the low-complexity regions that are defined by the cross_match algorithms. PCR_C: long-range PCR of cancer tissues;
PCR_N: long-range PCR of normal adjacent tissues; NG_C: NimbleGen sequence capture of DNAs from cancer tissues;
PCR_N: NimbleGen sequence capture of DNAs from normal adjacent tissue.
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and Armadillo repeats in the N-terminal portion; several
binding sites for b-catenin and the mammalian homologue of
discs large (DLG) protein in the C-terminal portion; 3 15-
amino acid repeats and 7 20-amino acid repeats in the middle
portion (Fodde, 2002; Senda et al., 2007; Smith et al., 1993).
APC down egulates the Wnt signaling pathway through its
binding to b-catenin and Axin (Smith et al., 1993). Inactivation
of APC in cancer is often due to truncations resulting from
mutations (Senda et al., 2007). Loss of the APC function results
in failure in inhibiting the Wnt signaling pathway, leading to
proliferation of cancer cells (Aoki and Taketo, 2007; Nishisho
et al., 1991). APC also binds other proteins such as the APC-
stimulated guanine nucleotide exchange factor, the kinesin
superfamily associated protein 3, IQGAP1, microtubules,
EB1, and DLG (Aoki and Taketo, 2007).
It was generally assumed that the pathogenicity of exonic
mutations result from predicted effects on the reading frame
and protein function. Traditionally, synonymous mutations
or benign nonsynonymous mutation were assumed not to
cause much changes in function of the coded protein. How-
ever, the recent discovery that mutations creating or abol-
ishing splicing enhancers and silencers can cause human
diseases (Cartegni et al., 2002; Pagani and Baralle, 2004)
changed our view. Accumulated evidence suggests that many
cancer-associated alternative-splicing events occur in the ab-
sence of mutations in the affected genes and they correlate
with cancer development, progression, and response to ther-
apy (Grosso et al., 2008). About 50–60% of the mutations that
cause diseases are found to affect splicing (Cartegni et al.,
2002; Lopez-Bigas et al., 2005). For example, Pagani et al.
(2005) recently showed that showed that about one-quarter of
even synonymous substitutions resulted in altered splicing in
their extensive and systematic mutation analysis of exons
9 and 12 of the CFTR gene, whose mutation causes cystic
fibrosis.
Alternative splicing provides a versatile means of genetic
regulation in metazoans. A single gene can generate multiple
transcripts by alternative splicing, thereby expanding the
transcriptome and proteome diversity. Removing of introns
from pre-mRNAs involves an assembly of snRNPs and ex-
trinsic, non-snRNP, protein-splicing factors, and pre-mRNAs
to form the spliceosome. Many specific sequences located at
and near the 5’ and 3’ splice sites, and in intronic regions can
modulate the association of the spliceosome with the pre-
mRNA, and affect alternative splicing. Six of the seven syn-
onymous mutations and the one nonsynonymous mutation
that we identified in the APC gene were predicted to result in a
change of ESE or ESS (Table 2). Mutations of ESE could reduce
inclusion of the corresponding exon into the mature mRNA
but mutations of an ESS increases inclusion of the exon. The
mutations in ESE or ESS could affect the specific binding of
regulatory proteins such as SR proteins (serine=
arginine-rich proteins) or heterogeneous nuclear (hn)RNPs
(Graveley, 2000). Some silencers, instead of binding regula-
tory proteins, can form a particular pre-mRNA secondary
structure that hinders the recognition of a neighboring splic-
ing enhancer by SR proteins (Buratti et al., 2004). The exact
mechanism of ESE=ESS gain or loss in the APC mutations that
we identified remains to be investigated. The mechanism
could be an inclusion or exclusion of exons coding for key
APC functional domains, or a change that affects the pro-
portions of different mRNA splicing isoforms and so on.
We also identified SNPs in the upstream regions that were
predicted to affect transcription factor binding sites in the
APC gene (Table 3), which may in turn, affect expression of
the APC gene. Three of these SNPs were only identified in the
cancer samples (Table 5). For example, Chr5:112063970 SNP
G->C would result in the gain of binding to two isoforms of
the Wilms’ tumor WT1 protein [WT1 I-KTS, alternative splice
variant of WT1 lacking 17 AA (250–266 SF of WT1þKTS) and
408–410 (K-T-S) and WT1KTS, alternative splice variant of
WT1 lacking AA 408–410 (K-T-S) of full-length WT1] and a
gain of ETF transcription factor. The Wilms’ Tumor 1-KTS
Isoform (WT1–KTS) can induce p53-independent apoptosis
(Menke et al., 1997). ETF specifically stimulates transcription
from promoters without a TATA box (Kageyama et al., 1989).
Chr5:112070456 SNP A->G would result in a loss of c-Ets-1
[T00112] binding. C-Ets-1 is a proto-oncogene that controls
the expression of many genes including a number of genes
involved in extracellular matrix remodeling (Reddy and Rao,
1988; Takai et al., 2000).
We compared the long-range PCR approach and the
NimbleGen’s target capture approach for obtaining specific
genomic regions for the next-generation sequencing. We no-
ticed that for the GC rich region, the PCR approach seemed to
perform better than the NimbleGen’s target capture approach.
Conclusions
We demonstrated an efficient approach for SNP discovery
in targeted genomics regions in a large number of samples
combining long-range PCR or NimbleGen sequence capture
and the next-generation sequencing technologies. Using one
of the most sequenced genes in the human genome—the APC
gene, we showed that this approach is effective by the iden-
tification 69 novel SNPs among 210 SNPs that we identified in
the colorectal cancers and normal adjacent tissues of Chinese
patients.
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